癌症研究
生物
趋化因子受体
免疫学
肺癌
归巢(生物学)
CXCR3型
趋化因子
免疫系统
医学
内科学
生态学
作者
Francesca Sozio,Tiziana Schioppa,Mattia Laffranchi,Valentina Salvi,Nicola Tamassia,Francisco M. Bianchetto-Aguilera,Laura Tiberio,Raffaella Bonecchi,Daniela Bosisio,Marc Parmentier,Barbara Bottazzi,Roberto Leone,Eleonora Russo,Giovanni Bernardini,Stefano Garofalo,Cristina Limatola,Angela Gismondi,Giuseppe Sciumè,Alberto Mantovani,Annalisa Del Prete,Silvano Sozzani
出处
期刊:Cancer immunology research
[American Association for Cancer Research]
日期:2023-06-21
卷期号:11 (9): 1280-1295
被引量:6
标识
DOI:10.1158/2326-6066.cir-22-0951
摘要
Abstract Patterns of receptors for chemotactic factors regulate the homing of leukocytes to tissues. Here we report that the CCRL2/chemerin/CMKLR1 axis represents a selective pathway for the homing of natural killer (NK) cells to the lung. C–C motif chemokine receptor-like 2 (CCRL2) is a nonsignaling seven-transmembrane domain receptor able to control lung tumor growth. CCRL2 constitutive or conditional endothelial cell targeted ablation, or deletion of its ligand chemerin, were found to promote tumor progression in a Kras/p53Flox lung cancer cell model. This phenotype was dependent on the reduced recruitment of CD27– CD11b+ mature NK cells. Other chemotactic receptors identified in lung-infiltrating NK cells by single-cell RNA sequencing (scRNA-seq), such as Cxcr3, Cx3cr1, and S1pr5, were found to be dispensable in the regulation of NK-cell infiltration of the lung and lung tumor growth. scRNA-seq identified CCRL2 as the hallmark of general alveolar lung capillary endothelial cells. CCRL2 expression was epigenetically regulated in lung endothelium and it was upregulated by the demethylating agent 5-aza-2′-deoxycytidine (5-Aza). In vivo administration of low doses of 5-Aza induced CCRL2 upregulation, increased recruitment of NK cells, and reduced lung tumor growth. These results identify CCRL2 as an NK-cell lung homing molecule that has the potential to be exploited to promote NK cell–mediated lung immune surveillance.
科研通智能强力驱动
Strongly Powered by AbleSci AI